1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer.
Saved in:
| Title: | 1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer. |
|---|---|
| Authors: | Rimmel, B.1 (AUTHOR), Bender, D.2 (AUTHOR), Enserro, D.3 (AUTHOR), Westin, S.4 (AUTHOR), Powell, M.A.5 (AUTHOR), Holman, L.6 (AUTHOR), Moore, R.G.7 (AUTHOR), Backes, F.8 (AUTHOR), Musa, F.B.9 (AUTHOR), DiSilvestro, P.10 (AUTHOR), Godbee, N.11 (AUTHOR), Gill, S.E.12 (AUTHOR), Leath III, C.A.13 (AUTHOR), Barber, E.14 (AUTHOR), Beffa, L.15 (AUTHOR), Aghajanian, C.16 (AUTHOR), Mackay, H.17 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS742-S742. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
